Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAGeoffrey R. Oxnard, Pasi A. Jänne, Cloud P. Paweletz et al.|Clinical Cancer Research|2014Cited by 781
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met OverexpressionMark M. Awad, Lynette M. Sholl, Priyanka Shivdasani et al.|Journal of Clinical Oncology|2016Cited by 687
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 InsertionsGeoffrey R. Oxnard, Pasi A. Jänne, Peter Lo et al.|Journal of Thoracic Oncology|2013Cited by 358
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Pasi A. Jänne, Xiaoyun Liao et al.|Journal of Thoracic Oncology|2015Cited by 290